ライフサイエンスコーパス: medical therapy

1 IABP-SHOCK II trial treated with an IABP or medical therapy.

2 s a pediatric liver disease with no approved medical therapy.

3 d ejection fraction with high use of optimal medical therapy.

4 al regurgitation (MR) on maximally-tolerated medical therapy.

5 ease with high mortality but has no approved medical therapy.

6 d patients compared with patients on maximal medical therapy.

7 58.3% of patients received all 4 classes of medical therapy.

8 icular assist device (LVAD) speed and direct medical therapy.

9 conservative strategy in addition to optimal medical therapy.

10 ng stents or CABG on a background of optimal medical therapy.

11 led open-angle glaucoma on maximum tolerated medical therapy.

12 nerve head changes despite maximal tolerated medical therapy.

13 eceived PCI and 24.7% were treated only with medical therapy.

14 in cases of aneurysms that do not respond to medical therapy.

15 ce daily]) in addition to guideline-directed medical therapy.

16 ing and standardized, blinded, target-driven medical therapy.

17 induced hypoglycemia that is unresponsive to medical therapy.

18 r-defibrillator and those randomized only to medical therapy.

19 yperresponsiveness despite receiving maximal medical therapy.

20 iple sclerosis tremor refractory to previous medical therapy.

21 d severe symptoms, which are unresponsive to medical therapy.

22 rization and 1010 patients were treated with medical therapy.

23 and 40 subjects (55 eyes) were randomized to medical therapy.

24 tion bias in patients chosen for surgical or medical therapy.

25 either percutaneous coronary intervention or medical therapy.

26 ) or placebo, in addition to guideline-based medical therapy.

27 constitute components of guideline directed medical therapy.

28 There is no known medical therapy.

29 wn to improve survival compared with optimal medical therapy.

30 lifestyle and risk factor modifications, and medical therapy.

31 et and/or progressing on maximally tolerated medical therapy.

32 heter interventions, and recommendations for medical therapy.

33 nce to healthy lifestyles and evidence-based medical therapies.

34 iotherapy techniques and availability of new medical therapies.

35 ns are not required to provide inappropriate medical therapies.

36 afety or threatens interruption of essential medical therapies.

37 adult IBD patients associated with available medical therapies.

38 "big data," phenomenology, and personalized medical therapies.

39 pectively (hazard ratio with PFO closure vs. medical therapy, 0.55; 95% confidence interval [CI], 0.3

40 ma related to the elective colectomy), 4.0%; medical therapy, 1.6%].

41 derate or fast in the medical therapy group (medical therapy, 11.5% vs. SLT, 8.3%; RR, 1.39; 95% CI,

42 ar pattern was observed for pointwise rates (medical therapy, 26.1% vs. SLT, 19.0%; RR, 1.37; 95% CI,

43 s of recurrence (6%) versus those treated by medical therapy (32%) [15% vs 61% at 5 years, adjusted h

44 t underwent moderate or fast PD progression (medical therapy, 9.9% vs. SLT, 7.1%; RR, 1.39; 95% CI, 0

45 valve replacement and the role of adjunctive medical therapy after TAVR.

46 several years in patients receiving optimal medical therapy, after successful PCI, does not influenc

47 y targeted manipulation of ROS for effective medical therapies against cancer or immunological disord

48 also evaluate new and ongoing research into medical therapies aimed at further reducing the risks of

49 lower incidence of death from any cause than medical therapy alone (182 deaths among 298 patients in

50 oglobin level than did patients who received medical therapy alone (2.1% vs. 0.3%, P=0.003).

51 s coronary intervention compared with either medical therapy alone (63% versus 21%) or coronary arter

52 of the PFO (PFO closure group) or to receive medical therapy alone (aspirin, warfarin, clopidogrel, o

53 e strategy) as compared with guideline-based medical therapy alone (conservative strategy) in partici

54 cal therapy (intervention group) or standard medical therapy alone (control group).

55 y (surgery group, 57 patients) or to receive medical therapy alone (medical-therapy group, 59 patient

56 ial effect of CABG plus medical therapy over medical therapy alone (P = 0.34 for interaction).

57 py or to an initial conservative strategy of medical therapy alone and angiography if medical therapy

58 initial conservative strategy consisting of medical therapy alone and angiography reserved for those

59 quality of life than did those who continued medical therapy alone at 12 months.

60 ower rate of recurrent ischemic strokes than medical therapy alone during extended follow-up.

61 on compared with those who received standard medical therapy alone in both per-protocol (28 [44%] of

62 al therapy was more effective than intensive medical therapy alone in decreasing, or in some cases re

63 ry artery bypass grafting [CABG]) or optimal medical therapy alone in patients with established coron

64 us medical therapy than in those who receive medical therapy alone is uncertain.

65 percutaneous coronary intervention to either medical therapy alone or coronary artery bypass graft su

66 were randomly assigned to receive intensive medical therapy alone or intensive medical therapy plus

67 Revascularization compared with medical therapy alone was not associated with a reduced

68 as met by 2 of 38 patients (5%) who received medical therapy alone, as compared with 14 of 49 patient

69 When compared with optimal medical therapy alone, patients with PCI experienced a M

70 When compared with optimal medical therapy alone, PCI was associated with MACCE red

71 d reduced HF rehospitalization compared with medical therapy alone.

72 ined health status improvement compared with medical therapy alone.

73 unction in patients with RH in comparison to medical therapy alone.

74 el occlusion results in better outcomes than medical therapy alone.

75 ected medical therapy, or guideline-directed medical therapy alone.

76 BG and receive medical therapy or to receive medical therapy alone.

77 ed when complications cannot be managed with medical therapy alone.

78 erapy compared with those receiving standard medical therapy alone.

79 -en-Y gastric bypass plus medical therapy or medical therapy alone.

80 rovascular thrombectomy with Solitaire FR or medical therapy alone.

81 re assessed by FFR and who were treated with medical therapy alone.

82 l interventions and in 13/25 who remained on medical therapy alone.

83 and 17 patients with cirrhosis who received medical therapy alone.

84 outcomes of revascularization compared with medical therapy among patients suitable for CABG.

85 re less likely to receive guideline-directed medical therapies and presented an increased risk for he

86 se has decreased, reflecting improvements in medical therapy and a more rigorous control of vascular

87 significant mortality benefit compared with medical therapy and a similar benefit compared with surg

88 rt failure patients under guideline-directed medical therapy and assessed sMR by effective regurgitan

89 cuss the mechanisms by which CSCs may resist medical therapy and contribute to tumor relapse.

90 dence supports the use of guideline-directed medical therapy and device-based therapies for the optim

91 drug metabolism, which has implications for medical therapy and drug development across multiple dis

92 he authors sought to evaluate trends in both medical therapy and lifestyle counseling for PAD patient

93 hen compared with patients not responding to medical therapy and not transplanted.

94 For both guideline-directed medical therapy and other recommended drug treatment reg

95 ocedure (right heart catheterization) versus medical therapy and PFO closure with the Amplatzer PFO O

96 review the scientific evidence in support of medical therapy and revascularization for the management

97 fying appropriate candidates for optimal CAD medical therapy and revascularization.

98 require reassessment given advances in both medical therapy and surgical techniques.

99 However, prompt guideline-directed medical therapy and transradial primary percutaneous cor

100 atic HFrEF taking optimal guideline-directed medical therapy and with a cardiac implantable electroni

101 ncluding the role of the gastric microbiota, medical therapies, and modifications in the stomach's mi

102 Treatments include transsphenoidal surgery, medical therapies, and radiotherapy.

103 Use of each class of medical therapy, and its composite use, was associated w

104 ion and treatment, initiate conservative and medical therapy, and refer to specialists when underlyin

105 devastating sarcomas for which no effective medical therapies are available.

106 No effective medical therapies are currently available to induce angi

107 Effective medical therapies are lacking for the treatment of neuro

108 Current medical therapies are nonspecific and have limited effic

109 egression identified compliance with optimal medical therapy as a more powerful predictor of major ad

110 rEF patients did not receive target doses of medical therapy at any point during follow-up, and few p

111 Fifty patients with residual CTEPH despite medical therapy at least 6 months after PEA, who had mea

112 cts or impaired bile flow with few effective medical therapies available.

113 10% and normalized (>50%) on evidence-based medical therapies (baseline echocardiogram).

114 care metrics: (1) prompt guideline-directed medical therapy before sheath insertion for PCI, (2) use

115 Prompt guideline-directed medical therapy before sheath insertion for PCI, transra

116 With the discovery of l-dopa the advent of medical therapy began and surgical approaches became les

117 py is generally transsphenoidal surgery with medical therapy being reserved for those not cured by su

118 allocated to catheter ablation of AF or best medical therapy (BMT).

119 either endovascular thrombectomy or standard medical therapy, by CTP as relative cerebral blood flow

120 eed for specific therapies besides optimised medical therapy can be determined.

121 Consequently, no medical therapy can be recommended for the stabilization

122 In comparison to conventional medical therapy, combined amniotic membrane transplantat

123 ntation to provide VNS (active) or continued medical therapy (control) in a 3:2 ratio.

124 trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with

125 studies that directly compared surgery with medical therapy did not report uniformly improved outcom

126 The addition of colchicine to standard medical therapy did not significantly affect cardiovascu

127 related quality of life and fatigue, whereas medical therapy did not.

128 strategy of catheter ablation, compared with medical therapy, did not significantly reduce the primar

129 FrEF on more contemporary guideline-directed medical therapies, discontinuation of pre-admission digo

130 mbined amniotic membrane transplantation and medical therapy does not accelerate corneal epithelializ

131 + secondary MR receiving maximally-tolerated medical therapy, edge-to-edge TMVr resulted in substanti

132 significantly between revascularization and medical therapy, either in the CABG stratum (26.1% vs. 2

133 H-related hospitalization, functional class, medical therapy escalation, and BNP [brain natriuretic p

134 of medical therapy alone and angiography if medical therapy failed.

135 ay require surgical reintervention and 59.5% medical therapy following antireflux surgery in England.

136 has not been shown for patients followed on medical therapy for advanced HF at centers that also off

137 t of endovascular thrombectomy over standard medical therapy for improved functional outcome.

138 ticosteroids, optic canal decompression, and medical therapy for indirect TON, the weight of publishe

139 Current and potential medical therapy for obstruction-induced myopathic bladde

140 to transcatheter mitral valve repair versus medical therapy for patients with heart failure and symp

141 aneous coronary interventions in addition to medical therapy for patients with stable coronary artery

142 smoking, and greater utilization of optimal medical therapy for prevention and treatment of CAD.

143 eceptor (MR) antagonists are the recommended medical therapy for primary aldosteronism.

144 A is feasible and has the potential to guide medical therapy for secondary prevention.

145 umber of clinical studies on the efficacy of medical therapy for systemic RV dysfunction.

146 randomized trials of PCI on a background of medical therapy for the treatment of CAD.

147 mated fashion, so as to support tailoring of medical therapies, for example, in the context of liver

148 failure, ejection fraction <=40%, on optimal medical therapy, functionally independent, and able to c

149 and dose up-titration of guideline-directed medical therapies (GDMT) for patients with heart failure

150 r with the MitraClip plus guideline-directed medical therapy (GDMT) (n = 302) versus GDMT alone (n =

151 d mortality compared with guideline-directed medical therapy (GDMT) alone.

152 to "guide" application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro-B-

153 with maximally tolerated guideline-directed medical therapy (GDMT) in patients with heart failure an

154 econdary MR randomized to guideline-directed medical therapy (GDMT) or edge-to-edge repair with the M

155 using the MitraClip plus guideline-directed medical therapy (GDMT) reduced 2-year rates of HF hospit

156 cular scaffold (BVS) plus guideline-directed medical therapy (GDMT) versus GDMT alone.

157 ic on maximally tolerated guideline-directed medical therapy (GDMT) were randomly assigned to MitraCl

158 Despite increased use of guideline-directed medical therapy (GDMT), some patients with heart failure

159 spite maximally tolerated guideline-directed medical therapy (GDMT).

160 were categorized as moderate or fast in the medical therapy group (medical therapy, 11.5% vs. SLT, 8

161 rwent moderate or fast TD progression in the medical therapy group compared with the SLT group (26.2%

162 PFO closure group and in 23 patients in the medical-therapy group (hazard ratio, 0.38; 95% CI, 0.18

163 %) in the surgery group and in 4 (7%) in the medical-therapy group (P<0.001).

164 The patients in the medical-therapy group were assigned to a waiting list fo

165 ups were superior to the changes seen in the medical-therapy group with respect to body weight (-23%,

166 closure group vs. 2669 patient-years in the medical-therapy group), owing to a higher dropout rate i

167 combined with extended-release dipyridamole; medical-therapy group).

168 tients) or to receive medical therapy alone (medical-therapy group, 59 patients).

169 PFO closure group and in 28 patients in the medical-therapy group, resulting in rates of 0.58 events

170 roup), owing to a higher dropout rate in the medical-therapy group.

171 common in the PFO closure group than in the medical-therapy group.

172 oup vs. 209 deaths among 303 patients in the medical-therapy group; adjusted hazard ratio, 0.73; 95%

173 the gastric-bypass, sleeve-gastrectomy, and medical-therapy groups, respectively), triglyceride leve

174 scular Society II-IV angina, despite optimal medical therapy, >/=1 myocardial segment with inducible

175 scular Society II-IV angina, despite optimal medical therapy, >/=1 myocardial segment with inducible

176 e and angiography reserved for those in whom medical therapy had failed.

177 hes, which include surgery, radiotherapy and medical therapy, have changed considerably over time owi

178 not offer a survival advantage over optimal medical therapy (HR, 0.95; 95% CI, 0.77-1.16) and there

179 he modern era of improved guideline-directed medical therapies, imaging of myocardial viability faile

180 e effect sizes for in-hospital and discharge medical therapies in a majority of RCTs were 3.0% to 10.

181 there have been only 5 randomized studies of medical therapies in HCM.

182 vestigate the potential benefit of TTVI over medical therapy in a propensity score matched population

183 idence with regard to a beneficial effect of medical therapy in adults with systemic RV dysfunction.

184 characterize longitudinal titration of HFrEF medical therapy in clinical practice and to identify ass

185 ME-CHF (Trial of Intensified Versus Standard Medical Therapy in Elderly Patients With Congestive Hear

186 olled trial compared ICD versus conventional medical therapy in high-risk patients with primary percu

187 nantly using stent retrievers) with standard medical therapy in patients with anterior circulation is

188 ndomized trials comparing PFO closure versus medical therapy in patients with cryptogenic stroke.

189 wever, neither procedure appears superior to medical therapy in patients with MELD score >=12.

190 MBS is superior to medical therapy in reducing hyperglycemia in persons wit

191 of coronary revascularization compared with medical therapy in the BARI-2D (Bypass Angioplasty Revas

192 were lower after revascularization than with medical therapy in the CABG stratum (15.3% vs. 30.3%, p

193 Unlike medical therapy, in which dosages are either prescribed

194 ceiving more contemporary guideline-directed medical therapies including beta-blockers and mineraloco

195 f hypercortisolism) is adenoma resection and medical therapies including ketoconazole, mifepristone,

196 fill dates, the utilization of 4 classes of medical therapy including statins, beta-blockers, angiot

197 h of symptom onset were randomly assigned to medical therapy (including intravenous alteplase when el

198 0.001) and lower rates of guideline-directed medical therapies, including aspirin (p < 0.001), statin

199 On admission, medical therapy, including angiotensin-converting enzyme

200 (1:1) to endovascular therapy plus standard medical therapy (intervention group) or standard medical

201 y and revascularization plus guideline-based medical therapy (invasive strategy) as compared with gui

202 is promoted and the penetration of systemic medical therapies is limited.

203 Medical therapy is an option for patients if surgery is

204 ich no Food and Drug Administration-approved medical therapy is available.

205 Medical therapy is currently an important treatment opti

206 Optimal medical therapy is endorsed by national guidelines in th

207 d brings into question what the true optimal medical therapy is for women versus men.

208 Optimal medical therapy is of recognized public health benefit.

209 ssive biliary tract disease without approved medical therapy, is not well understood.

210 brillation, catheter ablation, compared with medical therapy, led to clinically important and signifi

211 k Heart Association III/IVa symptoms despite medical therapy, left ventricular ejection fraction 25%

212 Therefore, patient compliance with medical therapy may inform clinical decision making and

213 RVD patients were treated with medical therapy (MT) and percutaneous transluminal renal

214 trials comparing catheter ablation (CA) with medical therapy (MT) in patients with atrial fibrillatio

215 (PCI) does not improve outcome compared with medical therapy (MT) in patients with stable coronary ar

216 surgical aortic valve replacement (SAVR) and medical therapy (MT).

217 Although most patients had no alterations in medical therapy, multiple clinical factors were independ

218 ention, including lifestyle changes, optimal medical therapy, myocardial revascularization and the us

219 ostoperative events requiring a procedure or medical therapy necessitating inpatient care.

220 risk of serious infections due to available medical therapies of inflammatory bowel disease (IBD) re

221 andomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina).

222 he left ventricle (LV) to guideline-directed medical therapy of heart failure, perhaps due to interve

223 2015, of 467 patients recruited, 428 started medical therapy, of whom 400 (93%) were evaluable at 52

224 xamines the current state-of-the-art optimal medical therapy (OMT) for patients with known coronary a

225 apnea were randomized to ASV plus optimized medical therapy (OMT) or OMT alone (control).

226 s graft (CABG) surgery combined with optimal medical therapy (OMT) was associated with lower MACCE ra

227 erm influence of compliance with recommended medical therapy on the comparative outcomes of CABG vers

228 ent elective surgery and 81% were treated by medical therapy on their second treatment encounter for

229 WL) to explore potential impact of effective medical therapy on WL registration.

230 e 0.170, 0.154, and 0.154 for CABG, PCI, and medical therapy only, respectively.

231 .6% received PCI and 87.4% were treated with medical therapy only.

232 ion, or a combination of MCS device use), or medical therapy only.

233 n to medical therapy while Group 2 continued medical therapy only.

234 treat cardiac risk factors through targeted medical therapies or healthy lifestyle changes.

235 revascularization (if appropriate) added to medical therapy or an initial conservative strategy cons

236 randomized to Roux-en-Y gastric bypass plus medical therapy or medical therapy alone.

237 omly assigned to atorvastatin-based standard medical therapy or standard therapy plus STS injection (

238 phy and revascularization when feasible) and medical therapy or to an initial conservative strategy o

239 andomly assigned to undergo CABG and receive medical therapy or to receive medical therapy alone.

240 c regulation therapy plus guideline-directed medical therapy, or guideline-directed medical therapy a

241 ulmonary artery pressures were used to guide medical therapy, or to the control group, in which daily

242 ility and the beneficial effect of CABG plus medical therapy over medical therapy alone (P = 0.34 for

243 Among medical therapy patients, a significant step-up increase

244 nce imaging, X-ray computer tomography), and medical therapies (photochemothermal therapies, immunoth

245 2014, 206 patients were randomly assigned to medical therapy plus endovascular treatment (n=103) or m

246 intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve

247 Intensive medical therapy refers to the contemporary approach of a

248 Outcomes with medical therapy remain suboptimal.

249 eated with RDN and 616 patients treated with medical therapy +/- sham procedure.

250 auses of osteoporosis or non-compliance with medical therapy should be considered.

251 Perioperative medical therapy should be prescribed based on patient-sp

252 What background medical therapy should we use?

253 le LDL apheresis and statins versus standard medical therapy (SMT) with no LDL apheresis and statin t

254 developed to assess the association between medical therapy status and major adverse cardiovascular

255 herapy (the revascularization group) or best medical therapy + structured exercise therapy (the nonre

256 udication to either revascularization + best medical therapy + structured exercise therapy (the revas

257 y demonstrates that on the basis of standard medical therapy, STS further reduce elevated hs-CRP and

258 ing cause of epilepsy along with appropriate medical therapy (surgery group, 57 patients) or to recei

259 Guideline-directed medical therapy, surgical mitral valve repair or replace

260 se who receive an invasive intervention plus medical therapy than in those who receive medical therap

261 , improvements in disease management and new medical therapies that are available and in development

262 Medical therapies that impact the progression of calcifi

263 tients with biliary atresia and there are no medical therapies that increase biliary drainage.

264 Personalized medical therapies that target the precise needs of patie

265 There is no proven medical therapy that attenuates adverse left ventricular

266 All comparisons of CABG to PCI or medical therapy that demonstrate survival effects with C

267 Great potential exists for successful medical therapy that halts or reduces aneurysm progressi

268 h increasing effectiveness of prevention and medical therapy, the role of coronary artery revasculari

269 with reduced ejection fraction (HFrEF) have medical therapy titrated to target doses derived from cl

270 aortic dissection (TBAD) has been aggressive medical therapy to achieve optimal heart rate and blood

271 ood pressure, may be a target for adjunctive medical therapy to improve outcomes after TAVR.

272 into a change of the treatment strategy from medical therapy to percutaneous coronary intervention.

273 ive and glaucoma patients treated first with medical therapy underwent rapid VF progression compared

274 nfectious keratitis unresponsive to standard medical therapy underwent RB-PDAT at the Bascom Palmer E

275 We sought to assess longitudinal trends in medical therapy use after PCI and its prognostic signifi

276 Consistent declines in medical therapy use following PCI were observed over tim

277 medication data and no contraindications to medical therapy, use and dose of angiotensin-converting

278 e despite the application of guideline-based medical therapy, use of ventricular assist devices and h

279 dary outcome measures included IOP, glaucoma medical therapy, visual acuity, and surgical complicatio

280 ndary outcome measures include IOP, glaucoma medical therapy, visual acuity, visual fields, and surgi

281 CABG plus medical therapy was associated with a lower incidence of

282 It soon became apparent, however, that medical therapy was associated with side effects in the

283 espectively, whereas no patient submitted to medical therapy was free of antihypertensive drugs at 12

284 f 27 to 43, bariatric surgery plus intensive medical therapy was more effective than intensive medica

285 D score >=12, survival after TAVR, SAVR, and medical therapy was similar (1.3 vs. 2.1 vs. 1.6 years,

286 Medical therapy was utilised in 57(46%) and sufficient f

287 s. 15.4%; p < 0.001), and guideline-directed medical therapies were used more frequently in the EXCEL

288 storm and cardiogenic shock despite optimal medical therapy were implanted with an extracorporeal li

289 Current medical therapies, which primarily consist of glucocorti

290 f 45-minute daily MM sessions in addition to medical therapy while Group 2 continued medical therapy

291 Randomized controlled trials comparing IBD medical therapies with no restrictions on language, coun

292 mortality and association of antithrombotic medical therapies with postdischarge 30-day stroke were

293 ith 30-day mortality, and the association of medical therapy with 30-day stroke risk.

294 istics over 1 year in subjects randomized to medical therapy with a sham procedure (right heart cathe

295 for symptomatic patients with obstruction is medical therapy with beta-blockers and calcium antagonis

296 g remote magnetic navigation for ablation or medical therapy with riociguat (MED group; n = 25).

297 Medical therapy with somatostatin analogues, cabergoline

298 m randomized, controlled trials that compare medical therapy with surgical therapy in patients with t

299 or had uncontrolled IOP on maximum-tolerated medical therapy, with medicated IOP >/=20 and </=35 mm H

300 of stroke and seizure for which no effective medical therapies yet exist.